Mental Health

April 3, 2023, News Staff — The Academy has unveiled a new on-demand CME activity for family physicians and other health care professionals that addresses several topics on mental and behavioral health. The activity, which launched March 30, allows participants to claim up to 11.75 AMA PRA Category 1 credits. Learning Objectives and Credits Participants who complete the activity will be able to develop evidence-based strategies and plans to effectively diagnose, treat and manage mental and behavioral health conditions commonly seen in primary care; prepare effective plans to diagnose, treat, and manage common mental and behavioral health conditions seen in primary care; prepare plans to take an equitable approach to patient counseling on behavior modification strategies to reduce risks of complications, and improve outcomes related to their mental and behavio

Abstract Bidirectional relationship between sleep disturbances and affective disorders is increasingly recognised, but its underlying mechanisms are far from clear, and there is a scarcity of studies that report on sleep disturbances in recurrent depressive disorder (RDD) and bipolar affective disorder (BPAD). To address this, we conducted a retrospective study of polysomnographic and clinical records of patients presenting to a tertiary sleep disorders clinic with affective disorders. Sixty-three BPAD patients (32 female; mean age ± S.D.: 41.8 ± 12.4 years) and 126 age- and gender-matched RDD patients (62 female; 41.5 ± 12.8) were studied. Whilst no significant differences were observed in sleep macrostructure parameters between BPAD and RDD patients, major differences were observed in comorbid sleep and physical disorders, both of which were higher in BPAD patients. Two most prevalent sleep disorders, namely obstructive sleep apnoea (OSA) (BPAD 50.8.0% vs RDD 29.3%, P  = 0

PHOENIX (3TV/CBS 5) -- Timing can be everything for the patient's and others' safety. One Valley facility is now intervening with faster solutions through their First Episode Center. "Had I not come in contact with the First Episode Center, I would not have had the recovery that I did," said Elise Lampley. In 2018, everything was going well for Lampley. She moved to Phoenix for her new tech job after graduating with a degree in chemical engineering from the University of Kentucky. But shortly after her move, Lampley stopped feeling like herself. "I could just feel like I was getting really sleepy and wasn't getting a lot of rest. I could hear voices, I thought people were out to get me," she explained. Her mom noticed too, and flew in to get help. But the treatment she needed was hard to come by. "Most places, they didn't know what was wrong with me," Lampley said. After struggling to get answers for months, she finally got a diagnosis. &qu

[unable to retrieve full-text content] Monitoring Men's Health: Mental Health Awareness Month | ksdk.com    KSDK.com

kubko_AdobeStock Uzedy (risperidone) extended-release injectable suspension has been approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. Uzedy, a product of Teva Pharmaceuticals, is now the first subcutaneous, long-acting formulation of risperidone that uses novel SteadyTeq to be approved by the FDA for the treatment of schizophrenia in this patient population. SteadyTeq is a copolymer technology proprietary to MedinCell that controls the release of risperidone over time, requiring no oral supplementation or loading dose and reaching therapeutic blood concentrations within 6 to 24 hours of each dose. 1 The FDA based its decision to approve the drug based on positive results from the SHINE Study—A Study to Test TV-46000 for Maintenance Treatment of Schizophrenia (TV46000-CNS-30078) and the RISE Study—The Risperidone Subcutaneous Extended-Release Study (TV46000-CNS-30072). 1 "UZEDY embodies Teva's commitment to bringing innovative

Brett Clementz doesn't love the term "schizophrenia." Sure, a quick glance down his extensive publication history might yield several uses of the word, but the University of Georgia Distinguished Research Professor finds it obsolete and imprecise. It doesn't capture the nature of the illness, he said, which is much more complex than society's common definition. The popular understanding goes something like this: An individual, usually a young adult, begins having hallucinations—"hearing voices" is a common description. Believing these misperceptions to be genuine, they lose their grip on reality and withdraw from family and friends. Taken to their conclusion, the symptoms may result in unpredictable and dangerous behavior. That's the popular belief. But it's not entirely accurate. In reality, there are far more factors that go into determining an individual's unique neurological disorder. Different behavioral symptoms

In the popular Netflix series The Crown , Princess Margaret is surprised to learn that she has two mentally disabled cousins who had, many years before, been hidden away and forgotten in a mental institution. Margaret, played by Helena Bonham Carter, voices the shock and anger many viewers experienced learning of this sad and, unfortunately, true story about the royal family. This was not such an unusual event, however. Hiding mental illness was once common practice for many families, who sought to avoid the shame and stigma associated with having such afflictions within the family. Mental health stigma refers to prejudice against people with mental illness. The American Psychiatric Association describes three types of stigma: public stigma, self-stigma, and institutional tigma. Public stigma refers to the negative attitudes society has toward persons with mental illness. When an individual with mental illness internalizes the attitudes, they experience self

In their efforts to understand the beneficial effects of SAINT, an important new fast-acting brain stimulation treatment for refractory major depression, researchers now think they understand why it works, and for whom. Remarkably, they propose, the treatment works because it helps to reverse the direction of signaling within an important brain network that is likely out of synch in major depression. The finding has potentially significant implications for fitting patients to the treatment and for understanding depression more generally. Last September, the U.S. Food and Drug Administration approved commercialization of SAINT for people with severe major depressive disorder who have not responded to multiple conventional antidepressant therapies. Developed by a team led by Nolan R. Williams, M.D., of Stanford University, a 2018 and 2016 BBRF Young Investigator and 2019 winner of BBRF's Klerman Prize for exceptional clinical research, SAINT has been impressive in three clinical